2Asian-Pacific Type 2 diabetes policy Group. Type 2 Diabetes Practice targets and treatments(Fourth Edition)[R]. 2005. 86.
3American Diabetes Association. Summary of Revisions for the 2007 Clinical Practice Recommendations Standards of Medical Care in Diabetes[J].Diabetes Care, 2007,30: S3-S40.
5UK Prospective Diabetes Study Group. Effect of intensive blood glucose control With metformin on complications in overweight patients with type 2 diabetes(UKPDS 34) [J].Lancet, 1998,352 : 854-865.
6Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin[J]. N Engl J Med, 2002,346 : 393-403.
7The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose; a randomized controlled trial[J]. Lancet, 2006,368: 1096-1105.
8Watts NB,DAlessio DA. Type 2 diabetes, thiazolidinediones: bad to the bone[J].J Clin Endocrinol Metab, 2006,91 : 3276-3278.
9Fonseca V, Grunberger G, Gupta S, et al. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glyeemic control[J].Diabetes Care, 2005,28:2093-2099.
10Chiasson JL, Josse RG, Gomis R, et al. diabetes mellitus: the STOP-NIDDM randomized tria[J]. Lancer, 2002,359: 2072.
8National Center for Health Statistics. Health, United States, 2004with chartbook on trends in the health of Americans. Hyattsville,Maryland: 2004. Available at: http://www. cdc. gov/nchs/data/hus/hus04. pdf. Accessible in Jan 2005.
9Katzmarzyk PT. The Canadian obesity epidemic: an historical perspective. Obesity Research, 2002,10: 666-674.
10Katzmarzyk PT, Ardem CI. Overweight and obesity mortality trends in Canada, 1985-2000. Can J Public Health, 2004,95: 16-20.
